← Leaderboards
Geert-Jan Boons
University Of Georgia (Uga)
$26,938,877
Attributed
$28,786,270
Total exposure
41
Grants
36
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$36,244,720 · 42
By mechanism
R01$19,167,766 · 7
P01$9,335,339 · 2
P41$4,132,403 · 30
U01$3,036,572 · 1
R56$562,640 · 1
R13$10,000 · 1
Top collaborators
- Kelley W. Moremen4 shared
- Stephen Mark Tompkins3 shared
Most similar at University Of Georgia (Uga)
Same institution · by research overlap
- Russell W Carlson$3,873,512
- James Michael Pierce$27,180,370
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseProteinsStructureCellsComplexOligosaccharidesPolysaccharidesCell SurfaceCarbohydratesBiologicalLinkImmune ResponseGlycosylationPathogenSignal TransductionMalignant NeoplasmsChemical SynthesisMethodologyPreparationGlycoconjugatesPatternModificationInflammationPrograms
Grant awards (108)
Automated chemo-enzymatic synthesis of N-glycans for host-pathogen interactions$849,692
R01 · FY2025 · AI · contact PI
Synthetic multi-component influenza vaccines to elicit broad immunity$660,492
R01 · FY2025 · AI · contact PI
Synthetic multi-component influenza vaccines to elicit broad immunity$665,022
R01 · FY2024 · AI · contact PI
Automated chemo-enzymatic synthesis of N-glycans for host-pathogen interactions$424,846
R01 · FY2024 · AI · contact PI
3-O-sulfation of heparan sulfate as a regular of protein function$451,658
R01 · FY2023 · HL · contact PI
Automated chemo-enzymatic synthesis of N-glycans for host-pathogen interactions$424,846
R01 · FY2023 · AI · contact PI
Automated chemo-enzymatic synthesis of N-glycans for host-pathogen interactions$469,846
R01 · FY2022 · AI · contact PI
3-O-sulfation of heparan sulfate as a regular of protein function$451,658
R01 · FY2022 · HL · contact PI
Synthetic multi-component influenza vaccines to elicit broad immunity$562,640
R56 · FY2021 · AI · contact PI
3-O-sulfation of heparan sulfate as a regular of protein function$451,658
R01 · FY2021 · HL · contact PI
3-O-sulfation of heparan sulfate as a regular of protein function$451,658
R01 · FY2020 · HL · contact PI
Streamlining the chemoenzymatic synthesis of asymmetrical glycans of biological importance$664,972
U01 · FY2019 · GM · contact PI
TR&D1. Integrated Approach for Ligand Identification and Validation$312,668
P41 · FY2019 · GM · contact PI
Streamlining the chemoenzymatic synthesis of asymmetrical glycans of biological importance$669,909
U01 · FY2018 · GM · contact PI
TR&D1. Integrated Approach for Ligand Identification and Validation$312,850
P41 · FY2018 · GM · contact PI
Streamlining the chemoenzymatic synthesis of asymmetrical glycans of biological importance$300,167
U01 · FY2018 · GM · contact PI
Mammalian Glycosyltransferases for use in Chemistry and Biology$1,491,780
P01 · FY2017 · GM · contact PI
Streamlining the chemoenzymatic synthesis of asymmetrical glycans of biological importance$665,728
U01 · FY2017 · GM · contact PI
Chemoenzymatic Synthesis of Highly Complex Glycans$376,841
P01 · FY2017 · GM · contact PI
TR&D1. Integrated Approach for Ligand Identification and Validation$312,850
P41 · FY2017 · GM · contact PI
Mammalian Glycosyltransferases for use in Chemistry and Biology$1,491,780
P01 · FY2016 · GM · contact PI
Streamlining the chemoenzymatic synthesis of asymmetrical glycans of biological importance$653,329
U01 · FY2016 · GM · contact PI
Chemoenzymatic Synthesis of Highly Complex Glycans$376,841
P01 · FY2016 · GM · contact PI
TR&D1. Integrated Approach for Ligand Identification and Validation$313,867
P41 · FY2016 · GM · contact PI
Novel chemoenzymatic approaches for the synthesis of complex glycans$270,000
R01 · FY2016 · GM · contact PI
Streamlining the chemoenzymatic synthesis of asymmetrical glycans of biological importance$82,467
U01 · FY2016 · GM · contact PI
Mammalian Glycosyltransferases for use in Chemistry and Biology$1,491,780
P01 · FY2015 · GM · contact PI
Chemoenzymatic Synthesis of Highly Complex Glycans$376,841
P01 · FY2015 · GM · contact PI
A Fully Synthetic Carbohydrate-based Cancer Vaccine$357,619
R01 · FY2015 · CA · contact PI
TR&D1. Integrated Approach for Ligand Identification and Validation$312,222
P41 · FY2015 · GM · contact PI
Novel chemoenzymatic approaches for the synthesis of complex glycans$269,550
R01 · FY2015 · GM · contact PI
Mammalian Glycosyltransferases for use in Chemistry and Biology$1,481,835
P01 · FY2014 · GM · contact PI
Synthetic Oligosaccharides for Probing Infection and Innate Immunity$407,257
R01 · FY2014 · GM · contact PI
Chemoenzymatic Synthesis of Highly Complex Glycans$374,328
P01 · FY2014 · GM · contact PI
A Fully Synthetic Carbohydrate-based Cancer Vaccine$346,890
R01 · FY2014 · CA · contact PI
Mammalian Glycosyltransferases for use in Chemistry and Biology$1,501,275
P01 · FY2013 · GM · contact PI
Synthetic Oligosaccharides for Probing Infection and Innate Immunity$393,004
R01 · FY2013 · GM · contact PI
Chemoenzymatic Synthesis of Highly Complex Glycans$372,038
P01 · FY2013 · GM · contact PI
A Fully Synthetic Carbohydrate-based Cancer Vaccine$336,162
R01 · FY2013 · CA · contact PI
Synthetic Oligosaccharides for Probing Infection and Innate Immunity$407,257
R01 · FY2012 · GM · contact PI
A Fully Synthetic Carbohydrate-based Cancer Vaccine$357,619
R01 · FY2012 · CA · contact PI
Novel Approaches for the synthesis of glycoprotein standards$291,090
R01 · FY2012 · GM · contact PI
NOVEL CLICK REAGENTS FOR GLYCOPROTEIN ISOLATION AND VISUALIZATION$442,858
P41 · FY2011 · RR · contact PI
Synthetic Oligosaccharides for Probing Infection and Innate Immunity$407,257
R01 · FY2011 · GM · contact PI
New synthetic methods for the preparation of carbohydrate-based vaccines$361,412
R01 · FY2011 · GM · contact PI
A Fully Synthetic Carbohydrate-based Cancer Vaccine$357,618
R01 · FY2011 · CA · contact PI
Novel Approaches for the synthesis of glycoprotein standards$337,782
R01 · FY2011 · GM · contact PI
ARTIFICIAL LECTINS$1,772
P41 · FY2011 · RR · contact PI
CHEMICAL SYNTHESIS OF SKP1 DERIVED GLYCOPEPTIDES FOR BIOCHEMICAL STUDIES$1,772
P41 · FY2011 · RR · contact PI
LIGANDS & BINDING SPECIFICITY OF THE PASTA DOMAINS OF M TUBERCULOSIS PROTEINS$1,772
P41 · FY2011 · RR · contact PI
GLYCOSAMINOGLYCAN STANDARD FOR HS IDENTIFICATION & QUANTITATIVE ANALYSIS$1,772
P41 · FY2011 · RR · contact PI
CHEMICAL SYNTHESIS OF PHOSPHOGLYCOPEPTIDES DERIVED FROM DYSTROGLYCAN$1,772
P41 · FY2011 · RR · contact PI
NOVEL CLICK REAGENTS FOR GLYCOPROTEIN ISOLATION AND VISUALIZATION$421,116
P41 · FY2010 · RR · contact PI
New synthetic methods for the preparation of carbohydrate-based vaccines$365,063
R01 · FY2010 · GM · contact PI
A fully synthetic carbohydrate-based cancer vaccine$355,210
R01 · FY2010 · CA · contact PI
Novel Approaches for the synthesis of glycoprotein standards$294,030
R01 · FY2010 · GM · contact PI
Novel Approaches for the synthesis of glycoprotein standards$45,964
R01 · FY2010 · GM · contact PI
Novel Approaches for the synthesis of glycoprotein standards$37,125
R01 · FY2010 · GM · contact PI
NEW SYNTHETIC ENDOTOXIN ANTAGONISTS$1,688
P41 · FY2010 · RR · contact PI
ARTIFICIAL LECTINS$1,685
P41 · FY2010 · RR · contact PI
MODULATION OF INNATE IMMUNE RESPONSES WITH SYNTHETIC LIPID A DERIVATIVES$1,685
P41 · FY2010 · RR · contact PI
MANNOSIDASE INHIBITORS$1,685
P41 · FY2010 · RR · contact PI
GLYCANS AND DEVELOPMENT$1,685
P41 · FY2010 · RR · contact PI
NOVEL CLICK REAGENTS FOR GLYCOPROTEIN ISOLATION AND VISUALIZATION$548,373
P41 · FY2009 · RR · contact PI
Elucidating structure-function relationships of lipid A: A synthetic approach$394,813
R01 · FY2009 · GM · contact PI
New synthetic methods for the preparation of carbohydrate-based vaccines$368,750
R01 · FY2009 · GM · contact PI
A fully synthetic carbohydrate-based cancer vaccine$348,241
R01 · FY2009 · CA · contact PI
Novel Approaches for the synthesis of glycoprotein standards$297,000
R01 · FY2009 · GM · contact PI
A fully synthetic carbohydrate-based cancer vaccine$151,510
R01 · FY2009 · CA · contact PI
NEW SYNTHETIC ENDOTOXIN ANTAGONISTS$2,219
P41 · FY2009 · RR · contact PI
RECOGNITION OF SYNTHETIC GRAM-POSITIVE AND NEGATIVE PEPTIDOGLYCAN FRAGMENTS$2,193
P41 · FY2009 · RR · contact PI
MODULATION OF INNATE IMMUNE RESPONSES WITH SYNTHETIC LIPID A DERIVATIVES$2,193
P41 · FY2009 · RR · contact PI
MANNOSIDASE INHIBITORS$2,193
P41 · FY2009 · RR · contact PI
Elucidating structure-function relationships of lipid A: A synthetic approach$386,996
R01 · FY2008 · GM · contact PI
New synthetic methods for the preparation of carbohydrate-based vaccines$368,750
R01 · FY2008 · GM · contact PI
A fully synthetic carbohydrate-based cancer vaccine$338,098
R01 · FY2008 · CA · contact PI
THE ROLE OF MULTIVALENCY IN THE MODE-OF-ACTION OF BACTERIAL SIALIDASES$263,971
P41 · FY2008 · RR · contact PI
NEW SYNTHETIC ENDOTOXIN ANTAGONISTS$1,408
P41 · FY2008 · RR · contact PI
Cellular Activation Induced by Multivalent Ligands$415,500
R01 · FY2007 · GM · contact PI
A fully synthetic carbohydrate-based cancer vaccine$334,751
R01 · FY2007 · CA · contact PI
Elucidating structure-function relationships of lipid A: A synthetic approach$328,446
R01 · FY2007 · GM · contact PI
THE ROLE OF MULTIVALENCY IN THE MODE-OF-ACTION OF BACTERIAL SIALIDASES$265,243
P41 · FY2007 · RR · contact PI
NEW SYNTHETIC ENDOTOXIN ANTAGONISTS$1,411
P41 · FY2007 · RR · contact PI
THE ROLE OF MULTIVALENCY IN THE MODE-OF-ACTION OF BACTERIAL SIALIDASES$343,251
P41 · FY2006 · RR · contact PI
Cellular Activation Induced by Multivalent Ligands$337,924
R01 · FY2006 · GM · contact PI
Elucidating structure-function relationships of lipid A: A synthetic approach$330,440
R01 · FY2006 · GM · contact PI
Cellular Activation Induced by Multivalent Ligands$80,495
R01 · FY2006 · GM · contact PI
SITE-SPECIFIC GLYCOSYLATION OF GLYCOLYLATED HUMAN IGG-FC ANTIBODIES$1,430
P41 · FY2006 · RR · contact PI
RECOGNITION OF SYNTHETIC GRAM-POSITIVE AND NEGATIVE PEPTIDOGLYCAN FRAGMENTS$1,430
P41 · FY2006 · RR · contact PI
NEW SYNTHETIC ENDOTOXIN ANTAGONISTS$1,430
P41 · FY2006 · RR · contact PI
Cellular Activation Induced by Multivalent Ligands$336,149
R01 · FY2005 · GM
Synthesis/Immunological Properties of Lewis Antigens$322,180
R01 · FY2005 · CA
THE ROLE OF MULTIVALENCY IN THE MODE-OF-ACTION$204,097
P41 · FY2005 · RR
2005 Carbohydrates Gordon Conference$10,000
R13 · FY2005 · RR
SITE-SPECIFIC GLYCOSYLATION OF GLYCOLYLATED HUMAN IGG-FC ANTIBODIES$1,366
P41 · FY2005 · RR
NEW SYNTHETIC ENDOTOXIN ANTAGONISTS$1,366
P41 · FY2005 · RR
Cellular Activation Induced by Multivalent Ligands$326,442
R01 · FY2004 · GM
Synthesis/Immunological Properties of Lewis Antigens$322,180
R01 · FY2004 · CA
SYNTHESIS AND EVALUATION OF NOVEL ENDOTOXIN ANTAGONISTS$289,600
R01 · FY2004 · GM
THE ROLE OF MULTIVALENCY IN THE MODE-OF-ACTION OF BACTERIAL SIALIDASES$41,910
P41 · FY2004 · RR
SITE-SPECIFIC GLYCOSYLATION OF GLYCOLYLATED HUMAN IGG-FC ANTIBODIES$600
P41 · FY2004 · RR
NEW SYNTHETIC ENDOTOXIN ANTAGONISTS$600
P41 · FY2004 · RR
Synthesis/Immunological Properties of Lewis Antigens$322,180
R01 · FY2003 · CA
SYNTHESIS AND EVALUATION OF NOVEL ENDOTOXIN ANTAGONISTS$289,600
R01 · FY2003 · GM
Synthesis/Immunological Properties of Lewis Antigens$322,180
R01 · FY2002 · CA
SYNTHESIS AND EVALUATION OF NOVEL ENDOTOXIN ANTAGONISTS$289,600
R01 · FY2002 · GM
SYNTHESIS AND EVALUATION OF NOVEL ENDOTOXIN ANTAGONISTS$289,600
R01 · FY2001 · GM
SYNTHESIS AND EVALUATION OF NOVEL ENDOTOXIN ANTAGONISTS$277,056
R01 · FY2000 · GM